Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Operating Expenses (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Operating Expenses for 5 consecutive years, with $62.8 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 26.27% to $62.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $228.0 million through Dec 2025, up 1.43% year-over-year, with the annual reading at $227.8 million for FY2025, 1.36% up from the prior year.
  • Operating Expenses hit $62.8 million in Q4 2025 for Krystal Biotech, up from $56.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $62.8 million in Q4 2025 to a low of $14.4 million in Q1 2021.
  • Historically, Operating Expenses has averaged $41.3 million across 5 years, with a median of $43.9 million in 2023.
  • Biggest five-year swings in Operating Expenses: soared 249.91% in 2022 and later fell 8.07% in 2025.
  • Year by year, Operating Expenses stood at $21.9 million in 2021, then soared by 58.95% to $34.8 million in 2022, then rose by 11.86% to $38.9 million in 2023, then rose by 27.94% to $49.8 million in 2024, then rose by 26.27% to $62.8 million in 2025.
  • Business Quant data shows Operating Expenses for KRYS at $62.8 million in Q4 2025, $56.4 million in Q3 2025, and $56.7 million in Q2 2025.